SteadyMed Announces FDA Agreed Pathway to Trevyent NDA Resubmission Post author:Sam Post published:December 7, 2017 Post category:BioPharma No clinical trials are required for the NDA resubmission. Source: BioSpace You Might Also Like Medovex Corporation Receives CE Mark Approval For DenerveX System June 6, 2017 San Diego's Denovo Biopharma Opens Doors to New R&D Center, Names New CMO and CFO January 2, 2018 3 Biotechs Breathing Down Bristol-Myers Squibb's Neck February 2, 2017
